期刊
CARDIOVASCULAR DIABETOLOGY
卷 18, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s12933-019-0860-y
关键词
Metformin; Diabetes mellitus; Coronary artery disease; Atherosclerosis
资金
- Hunan Provincial Innovation Foundation for Postgraduate [CX2018B068]
- Hunan Provincial Natural Science Foundation of China [2018JJ2587]
- National Natural Science Foundation of China [81570267, 31670816]
With an increasing global burden of coronary artery disease (CAD), early detection and timely management of risk factors are crucial to reduce morbidity and mortality in such patients. Diabetes mellitus (DM) is considered an independent risk factor for the development of CAD. Metformin, an anti-diabetic drug, has been shown in pre-clinical and clinical studies, to lower the cardiovascular events in the DM patients. Growing evidence suggests that metformin has a protective effect on coronary artery beyond its hypoglycemic effects. Given its global availability, route of administration and cost, metformin provides an alternate/additional therapeutic option for primary and secondary prevention of CAD in DM and non-diabetics alike. Future prospective cohort-based studies and randomized clinical trials are needed to identify at-risk' population who may potentially benefit from metformin.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据